Where can I find 688393.SS's financial statements?

Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for 688393.SS?

Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does 688393.SS update its statements?

Guangzhou LBP Medicine Science & Technology Co., Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

688393.SS

Guangzhou LBP Medicine Science & Technology Co., Ltd.

SHH·Medical, Instruments & Supplies · Healthcare

¥20.22¥0.19−0.93%

Market cap¥1.89B·Market closed·Aug 27 2:23 AM UTC

CNY · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	¥438.99M+16.9%	¥507.38M+15.6%	¥497.29M−2.0%	¥470.79M−5.3%	¥342.25M−27.3%
Cost of revenue	¥98.60M+29.4%	¥148.97M+51.1%	¥161.87M+8.7%	¥159.61M−1.4%	¥125.22M−21.5%
Gross profit	¥340.39M+13.8%	¥358.41M+5.3%	¥335.42M−6.4%	¥311.18M−7.2%	¥219.22M−29.6%
Research & development	¥45.90M+65.5%	¥67.39M+46.8%	¥62.69M−7.0%	¥45.47M−27.5%	¥36.06M−20.7%
General & administrative	¥52.96M+62.7%	¥75.82M+43.2%	¥77.13M+1.7%	¥71.34M−7.5%	¥3.23M−95.5%
Selling & marketing	¥179.07M+16.9%	¥184.32M+2.9%	¥181.66M−1.4%	¥191.48M+5.4%	¥90.08M−53.0%
SG&A (combined)	¥232.02M+24.9%	¥260.14M+12.1%	¥258.79M−0.5%	¥262.83M+1.6%	¥93.31M−64.5%
Other operating expenses	−¥26.47M−83.8%	¥2.19M+108.3%	−¥7.57M−445.0%	−¥8.11M−7.1%	¥141.28M+1,842.4%
Total operating expenses	¥251.45M+26.3%	¥329.73M+31.1%	¥313.91M−4.8%	¥300.18M−4.4%	¥270.65M−9.8%
Operating income	¥88.94M−11.2%	¥28.68M−67.8%	¥21.51M−25.0%	¥11.00M−48.9%	−¥71.57M−750.5%
Interest income	¥19.21M+208.7%	¥7.69M−59.9%	¥8.80M+14.3%	¥9.17M+4.2%	¥5.93M−35.3%
Interest expense	¥524.99K+611.7%	¥1.36M+158.8%	¥808.03K−40.5%	¥854.87K+5.8%	¥636.39K−25.6%
Other income / (expense), net	−¥216.43K+36.9%	¥110.65K+151.1%	−¥4.66M−4,314.6%	−¥1.57M+66.4%	¥16.40M+1,146.5%
Income before tax	¥88.72M−11.1%	¥28.79M−67.5%	¥16.85M−41.5%	¥9.43M−44.0%	−¥55.16M−684.7%
Income tax expense	¥13.44M−17.2%	−¥539.23K−104.0%	−¥4.17M−673.2%	−¥5.47M−31.1%	−¥4.36M+20.2%
Net income	¥79.78M−5.9%	¥42.69M−46.5%	¥40.06M−6.2%	¥21.29M−46.8%	−¥47.02M−320.9%

EPS (basic)	¥0.85−22.0%	¥0.46−45.9%	¥0.43−6.5%	¥0.23−46.5%	−¥0.50−317.4%
EPS (diluted)	¥0.85−22.0%	¥0.45−47.1%	¥0.42−6.7%	¥0.23−45.2%	−¥0.50−317.4%
Weighted avg shares (basic)	93,853,851	94,876,186	95,374,316	92,570,930	93,691,041
Weighted avg shares (diluted)	93,853,851	94,876,186	95,374,316	92,570,930	93,691,041

Depreciation & amortization	¥16.53M+58.0%	¥32.35M+95.8%	¥38.20M+18.1%	¥38.24M+0.1%	¥51.80M+35.5%
EBITDA	¥105.63M−4.3%	¥62.50M−40.8%	¥55.86M−10.6%	¥48.53M−13.1%	−¥19.77M−140.7%

Frequently Asked Questions About 688393.SS

Where can I find 688393.SS's financial statements?: Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for 688393.SS?: Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does 688393.SS update its statements?: Guangzhou LBP Medicine Science & Technology Co., Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

¥438.99M+16.9%

¥507.38M+15.6%

¥497.29M−2.0%

¥470.79M−5.3%

¥342.25M−27.3%

Cost of revenue

¥98.60M+29.4%

¥148.97M+51.1%

¥161.87M+8.7%

¥159.61M−1.4%

¥125.22M−21.5%

Gross profit

¥340.39M+13.8%

¥358.41M+5.3%

¥335.42M−6.4%

¥311.18M−7.2%

¥219.22M−29.6%

Research & development

¥45.90M+65.5%

¥67.39M+46.8%

¥62.69M−7.0%

¥45.47M−27.5%

¥36.06M−20.7%

General & administrative

¥52.96M+62.7%

¥75.82M+43.2%

¥77.13M+1.7%

¥71.34M−7.5%

¥3.23M−95.5%

Selling & marketing

¥179.07M+16.9%

¥184.32M+2.9%

¥181.66M−1.4%

¥191.48M+5.4%

¥90.08M−53.0%

SG&A (combined)

¥232.02M+24.9%

¥260.14M+12.1%

¥258.79M−0.5%

¥262.83M+1.6%

¥93.31M−64.5%

Other operating expenses

−¥26.47M−83.8%

¥2.19M+108.3%

−¥7.57M−445.0%

−¥8.11M−7.1%

¥141.28M+1,842.4%

Total operating expenses

¥251.45M+26.3%

¥329.73M+31.1%

¥313.91M−4.8%

¥300.18M−4.4%

¥270.65M−9.8%

Operating income

¥88.94M−11.2%

¥28.68M−67.8%

¥21.51M−25.0%

¥11.00M−48.9%

−¥71.57M−750.5%

Interest income

¥19.21M+208.7%

¥7.69M−59.9%

¥8.80M+14.3%

¥9.17M+4.2%

¥5.93M−35.3%

Interest expense

¥524.99K+611.7%

¥1.36M+158.8%

¥808.03K−40.5%

¥854.87K+5.8%

¥636.39K−25.6%

Other income / (expense), net

−¥216.43K+36.9%

¥110.65K+151.1%

−¥4.66M−4,314.6%

−¥1.57M+66.4%

¥16.40M+1,146.5%

Income before tax

¥88.72M−11.1%

¥28.79M−67.5%

¥16.85M−41.5%

¥9.43M−44.0%

−¥55.16M−684.7%

Income tax expense

¥13.44M−17.2%

−¥539.23K−104.0%

−¥4.17M−673.2%

−¥5.47M−31.1%

−¥4.36M+20.2%

Net income

¥79.78M−5.9%

¥42.69M−46.5%

¥40.06M−6.2%

¥21.29M−46.8%

−¥47.02M−320.9%

EPS (basic)

¥0.85−22.0%

¥0.46−45.9%

¥0.43−6.5%

¥0.23−46.5%

−¥0.50−317.4%

EPS (diluted)

¥0.85−22.0%

¥0.45−47.1%

¥0.42−6.7%

¥0.23−45.2%

−¥0.50−317.4%

Weighted avg shares (basic)

93,853,851

94,876,186

95,374,316

92,570,930

93,691,041

Weighted avg shares (diluted)

93,853,851

94,876,186

95,374,316

92,570,930

93,691,041

Depreciation & amortization

¥16.53M+58.0%

¥32.35M+95.8%

¥38.20M+18.1%

¥38.24M+0.1%

¥51.80M+35.5%

EBITDA

¥105.63M−4.3%

¥62.50M−40.8%

¥55.86M−10.6%

¥48.53M−13.1%

−¥19.77M−140.7%